Risk Factors of Daptomycin-Induced Eosinophilic Pneumonia in a Population with Osteoarticular Infection

Laura Soldevila-Boixader; Bernat Villanueva; Marta Ulldemolins; Eva Benavent; Ariadna Padulles; Alba Ribera; Irene Borras; Javier Ariza; Oscar Murillo

doi:10.3390/antibiotics10040446

Risk Factors of Daptomycin-Induced Eosinophilic Pneumonia in a Population with Osteoarticular Infection

Antibiotics (Basel). 2021 Apr 16;10(4):446. doi: 10.3390/antibiotics10040446.

Authors

Laura Soldevila-Boixader^{1

2}, Bernat Villanueva¹, Marta Ulldemolins¹, Eva Benavent^{1

2}, Ariadna Padulles³, Alba Ribera^{1

2}, Irene Borras¹, Javier Ariza^{1

2

4}, Oscar Murillo^{1

2

4}

Affiliations

¹ Infectious Diseases Service, IDIBELL-Hospital Universitari Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907 Barcelona, Spain.
² Bone and Joint Infection Study Group of the Spanish Society of Clinical Microbiology and Infectious Diseases (GEIO-SEIMC), 28003 Madrid, Spain.
³ Pharmacy Department, IDIBELL-Hospital Universitari Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907 Barcelona, Spain.
⁴ Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003), Instituto de Salud Carlos III, 28029 Madrid, Spain.

Abstract

Background: Daptomycin-induced eosinophilic pneumonia (DEP) is a rare but severe adverse effect and the risk factors are unknown. The aim of this study was to determine risk factors for DEP.

Methods: A retrospective cohort study was performed at the Bone and Joint Infection Unit of the Hospital Universitari Bellvitge (January 2014-December 2018). To identify risk factors for DEP, cases were divided into two groups: those who developed DEP and those without DEP.

Results: Among the whole cohort (n = 229) we identified 11 DEP cases (4.8%) and this percentage almost doubled in the subgroup of patients ≥70 years (8.1%). The risk factors for DEP were age ≥70 years (HR 10.19, 95%CI 1.28-80.93), therapy >14 days (7.71, 1.98-30.09) and total cumulative dose of daptomycin ≥10 g (5.30, 1.14-24.66).

Conclusions: Clinicians should monitor cumulative daptomycin dosage to minimize DEP risk, and be cautious particularly in older patients when the total dose of daptomycin exceeds 10 g.

Keywords: daptomycin; eosinophilic pneumonia; risk factors.